LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Total immunoreactive level (immunologic/quantitative)
2 - 4 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
0.5 mL (Note: This volume does not allow for repeat testing.)
Red-top tube or gel-barrier tube
Separate serum from cells within 30 to 60 minutes after collection. Transfer specimen to a plastic transport tube.
Maintain specimen at room temperature.
Microbially-contaminated samples; hemolysis; gross lipemia that cannot be cleared by ultracentrifugation; citrated plasma (heparinized plasma is acceptable)
C1 esterase inhibitor is decreased in hereditary angioneurotic edema; decrease may be functional or quantitative
The more common form (85% of patients) of hereditary angioneurotic edema is due to an absolute decrease in the amount of C1 esterase inhibitor. A less common form (15% of patients) is due to a functional defect where quantitative levels may be normal. Both abnormalities must be tested for due to the potential life-threatening nature of the illness.
In addition to decreased C1 esterase inhibitor in the serum of patients with hereditary angioneurotic edema, a unique polypeptide kinin is increased in plasma from C1 esterase inhibitor deficient patient during attacks of swelling. Danazol, a synthetic androgenic inhibitor of gonadotropin release, with little virilizing potential, decreases the number of clinical attacks in cases of hereditary angioneurotic edema. Patients with attacks of hereditary angioneurotic edema also have low total complement, C4 and C2. Consequently, measurement of serum C4 is an often used test. Hereditary angioneurotic edema is transmitted as an autosomal dominant trait. Heterozygotes also show decreased levels of C1 esterase inhibitor. During acute attacks of the disease, complement factors C4 and C2 can be markedly reduced, but C1 and C3 are normal. The initiating stimulus of clinical attacks is often unknown.
Angioedema may also be an acquired illness. The acquired form includes nonhereditary C1 esterase deficiency; drug induced, allergic, and idiopathic forms, angioedema associated with autoimmune disease, especially with systemic lupus erythematosus and hypereosinophilia; angioedema occasionally associated with malignancy; and angioedema caused by physical stimuli. Angioedema has occasionally been known to precede development of lymphoproliferative disorders.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|004648||C1 Esterase Inhibitor, Serum||4477-6||004648||C1 Esterase Inhibitor, Serum||mg/dL||4477-6|
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf